|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 1.835 USD | -0.81% |
|
-11.78% | +86.75% |
Company Valuation: Fate Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,587 | 980.4 | 368.8 | 187.9 | 113.3 | 219.9 | - | - |
| Change | - | -82.45% | -62.39% | -49.04% | -39.69% | 93.98% | - | - |
| Enterprise Value (EV) | 4,971 | 544.2 | 53.6 | -118.8 | 113.3 | 219.9 | 219.9 | 219.9 |
| Change | - | -89.05% | -90.15% | -321.66% | 195.41% | 93.98% | 0% | 0% |
| P/E | -26.1x | -3.47x | -2.28x | -1.01x | -0.85x | -1.72x | -1.77x | -1.63x |
| PBR | 8.25x | 2.03x | 0.98x | 0.59x | - | - | - | - |
| PEG | - | -0.1x | 0.1x | - | 0x | 0.24x | 0.57x | -0.19x |
| Capitalization / Revenue | 100x | 10.2x | 5.8x | 13.8x | 17.1x | 41.2x | 46.1x | 54.9x |
| EV / Revenue | 0x | 0x | 0x | -0x | 0x | 41.2x | 46.1x | 54.9x |
| EV / EBITDA | -0x | -0x | -0x | 0x | -0x | -1.79x | -1.44x | - |
| EV / EBIT | -0x | -0x | -0x | 0x | -0x | -1.63x | -1.45x | -1.23x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -1.98x | -1.86x | -1.62x |
| FCF Yield | -3.82% | -28.9% | -37.5% | -65.8% | -98.8% | -50.5% | -53.7% | -61.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 | -1.068 | -1.035 | -1.124 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 55.85 | 96.3 | 63.53 | 13.63 | 6.646 | 5.337 | 4.767 | 4.008 |
| EBITDA 1 | -211.1 | -294.6 | -172.2 | -191.3 | -134.8 | -122.7 | -153.1 | - |
| EBIT 1 | -217 | -308.4 | -190.5 | -210.3 | -147.7 | -134.7 | -151.5 | -178.9 |
| Net income 1 | -212.2 | -281.7 | -160.9 | -186.3 | -136.3 | -128.8 | -146 | -179 |
| Net Debt | -615.9 | -436.2 | -315.2 | -306.7 | - | - | - | - |
| Reference price 2 | 58.510 | 10.090 | 3.740 | 1.650 | 0.983 | 1.835 | 1.835 | 1.835 |
| Nbr of stocks (in thousands) | 95,494 | 97,170 | 98,602 | 113,894 | 115,352 | 119,821 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 3/5/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73x | - | - | -.--% | 220M | |
| 18.32x | 6.97x | 13.35x | 1.63% | 65.94B | |
| 39.18x | 6.93x | 20.69x | 0.83% | 56.53B | |
| 30.72x | 8.25x | 27.72x | 0.05% | 56.88B | |
| 51.08x | 5.91x | 32.37x | -.--% | 46.49B | |
| 34.57x | 3.29x | 14.19x | -.--% | 44.8B | |
| -18.44x | 177.78x | -19.56x | -.--% | 41.59B | |
| 36.57x | 9x | 23.45x | 0.36% | 35.35B | |
| 44.16x | 7.87x | 26.34x | -.--% | 33.29B | |
| 29.41x | 6.22x | 16.14x | -.--% | 24.92B | |
| Average | 26.38x | 25.80x | 17.19x | 0.29% | 40.6B | |
| Weighted average by Cap. | 29.12x | 24.33x | 17.40x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- FATE Stock
- Valuation Fate Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
